- Kalytera Therapeutics (TSXV:KLY) has welcomed new and promising data about its soon-to-be acquired drug, R-107
- The study showed that R-107 reduced tissue damage and preserved organ function in mice with symptoms similar to COVID-19’s
- Kalytera recently entered into a binding letter of intent to acquire Salzman Group, the company that currently owns the R-107 drug
- Kalytera intends to submit applications to Australian and US authorities for a clinical study of R-107 in COVID-19 patients
- Kalytera Therapeutics (KLY) is up 20.00 per cent and is currently trading at three cents per share
Kalytera Therapeutics (TSXV:KLY) has welcomed new and promising data about its soon-to-be acquired drug, R-107.
A study examined the drug’s effects on a sepsis-like syndrome in rodents, which produces similar symptoms to COVID-19-related lung disease. The study was designed to mimic the life-threatening circulatory shock and organ failure found in some COVID-19 infections.
The rodent version of sepsis was severe, with a 90 per cent mortality rate within a week. The condition also caused tissue injuries in the lungs, kidneys, pancreas, intestines, and liver.
In the study, the R-107 drug created positive results, by reducing tissue damage and preserving organ function. Over a week of follow-up, the septic mice’s survival rate jumped from 10 per cent to 90 per cent.
On May 19, Kalytera Therapeutics announced that it had entered into a binding letter of intent to acquire Salzman Group. The soon-to-be acquired company is a pharmaceutical development firm and the owner of the R-107 drug.
R-107 already has issued and pending patents for its composition of matter and method of use in approximately 40 countries. These includes Australia, the US, Brazil, China, Europe, India, Japan, Russia, and South Korea.
Kalytera Therapeutic’s CEO, Robert Farrell, said the company finds the results highly encouraging.
“The results of this study demonstrate the potential of R-100, the active payload of R-107, to block tissue injury in an aggressive and clinically-predictive model of lethal sepsis in the mouse.
“We plan to clinically explore its efficacy in COVID-19 pulmonary infection and acute lung injury. We are also exploring its potential in other forms of acute lung injury, such as chlorine inhalation lung injury, smoke inhalation injury, and bacterial sepsis,” he said.
Kalytera intends to submit an Investigational New Drug Application to the Australian Therapeutic Goods Administration and the US FDA. Once the company gains regulatory approval, it will start trials of R-107 in patients with COVID-19 associated pneumonia.
Kalytera Therapeutics (KLY) is up 20.00 per cent and is trading at three cents per share at 12:30pm EDT.